Pharmacological characteristics and regulation of 5-HT receptor-stimulatedphosphoinositide hydrolysis in the rat spinal cord

Citation
E. Toscano et al., Pharmacological characteristics and regulation of 5-HT receptor-stimulatedphosphoinositide hydrolysis in the rat spinal cord, GEN PHARM, 32(3), 1999, pp. 351-358
Citations number
46
Categorie Soggetti
Pharmacology & Toxicology
Journal title
GENERAL PHARMACOLOGY
ISSN journal
03063623 → ACNP
Volume
32
Issue
3
Year of publication
1999
Pages
351 - 358
Database
ISI
SICI code
0306-3623(199903)32:3<351:PCARO5>2.0.ZU;2-D
Abstract
In slices from immature rat spinal cord, both 5-hydroxytryptamine (5-HT) an d the 5-HT2A/C receptor agonists (+/-)-1-(2, 5-dimethoxy-4-iodophenyl)-2-am inopropane (DOI) and alpha-methyl-5-HT (alpha-Me-5-HT) stimulate phosphoino sitide (PI) hydrolysis. PI breakdown is also increased by the 5-HT3 recepto r agonist 2-Me-5-HT but not by phenylbiguanide. The effect of either 5-HT o r DOI is blocked by selective 5-HT2A receptor antagonists such as spiperone and ketanserin and more markedly by mixed 5-HT2 receptor antagonists, such as ritanserin, methysergide and mesulergine, with higher affinity at the 2 C subtype. The effect of 2-Me-5-HT is blocked by 5-HT2 and not by 5-HT3 rec eptor antagonists, indicating that 5-HT3 receptors do not directly or indir ectly take part in PI hydrolysis in the spinal cord. Moreover, lesion with neonatal capsaicin of thin primary afferents to the dorsal spinal cord enha nces inositol phosphate formation stimulated by 5-HT or DOI but not by 2-Me -5-HT. This lesion also increases 5-HT2A and 5-HT2C receptor density. After neonatal injection of 5,7-dihydroxytryptamine, which results in a marked l oss of 5-HT content in the cord, 5-HT and 5-HT2 receptor agonists also enha nce PI breakdown without a concomitant change in receptor number. The resul ts suggest that the 5-HT-stimulated PI response in the rat spinal cord is a ssociated only with the 5-HT2 receptor class, in particular with the 5-HT2C subtype. (C) 1999 Elsevier Science Inc. All rights reserved.